Dyne Therapeutics Announces Presentations at Major Conference
Dyne Therapeutics, Inc (NASDAQ: DYN), primarily known for its dedication to advancing therapeutics for neuromuscular diseases, is gearing up to showcase its innovative research at the upcoming MDA Clinical & Scientific Conference. This event is scheduled to take place from March 16-19, 2025, and will feature a blend of oral and poster presentations highlighting data from its ongoing clinical trials.
Key Presentations to Highlight Therapeutic Progress
During this pivotal conference, Dyne plans to present two oral sessions and five poster sessions that will provide valuable insights into the DELIVER and ACHIEVE clinical trials. The oral presentations will cover critical findings from the Phase 1/2 DELIVER trial focusing on Duchenne muscular dystrophy (DMD) and the positive outcomes of the ACHIEVE trial related to myotonic dystrophy type 1 (DM1).
Overview of Oral Presentations
The first oral presentation, titled "Safety and Efficacy from the Ongoing Phase 1/2 DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping," will be presented on March 19 by Dr. Kevin Flanigan. This presentation is crucial as it outlines the safety and efficacy results relating to the treatment methods being trialed. Following this, Dr. James Lilleker will speak on the efficacy of DYNE-101 in adults with DM1, summarizing key findings from the ACHIEVE trial.
Poster Presentations to Explore Various Aspects
In addition to the oral presentations, Dyne will also showcase five significant poster presentations. These will delve into various aspects of their research, including:
- The safety and efficacy of DYNE-251 in patients with DMD.
- Insights from the Phase 1/2 ACHIEVE trial focusing on adults with DM1.
- Characterization of patients with DM1 requiring complex care.
- Effects of the FORCE™ platform on DUX4 suppression in a mouse model.
- Delivery mechanisms of the FORCE™ platform targeting central nervous system needs.
Symposium on Advancing Targeted Therapies
On March 18, Dyne will host a symposium titled "Harnessing the FORCE™ Platform to Advance Targeted Therapies for Neuromuscular Diseases." This event will explore the key features of Dyne’s platform and present data from its leading clinical programs in DMD and DM1. The discussion will also touch upon exciting developments regarding splicing correction as a biomarker for functional outcomes in DM1 patients.
About Dyne Therapeutics
Dyne Therapeutics is at the forefront of developing innovative therapies for genetically driven neuromuscular conditions. The company’s FORCE™ platform is designed to enable targeted delivery of therapeutics specifically to muscle tissue and the central nervous system. This impressive pipeline includes clinical developments focused on myotonic dystrophy and Duchenne muscular dystrophy, alongside preclinical initiatives targeting other muscular dystrophies.
Frequently Asked Questions
What types of presentations will Dyne Therapeutics give at the conference?
Dyne will present two oral presentations and five poster presentations focusing on their ongoing clinical trials for DMD and DM1.
When is the MDA Clinical & Scientific Conference scheduled?
The conference will take place from March 16 to 19, 2025.
Who are the main presenters for Dyne's oral sessions?
Dr. Kevin Flanigan and Dr. James Lilleker will present key findings from their respective trials.
What is the focus of the symposium hosted by Dyne Therapeutics?
The symposium will explore advancements in targeted therapies for neuromuscular diseases using the FORCE™ platform.
What other conditions is Dyne Therapeutics targeting aside from DMD and DM1?
Dyne is also exploring therapies for conditions such as facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease in their research pipeline.
